Post
of 721
NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Technology Accelerates Delivery of CBD into Bloodstream
Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) 2.0 version of its patented DehydraTECH(TM) oral drug-delivery technology has demonstrated its power to deliver more cannabidiol (“CBD”) into the bloodstream than generic industry-control formulations (http://nnw.fm/SR9dw). An article discussing the company reads, “The company’s 2.0 technology is specifically being developed for effectiveness in helping to deliver its drug payload across the blood-brain barrier, a natural biological system of blood vessels and endothelial cells that bar most drugs from accessing the brain’s central-nervous-system hierarchy. The ability to effectively deliver drugs to the brain is of keen interest to developers of drugs designed to beneficially target the central nervous system. . . . Lexaria’s research and development showed that DehydraTECH version 2.0 was able to deliver 1,937% more CBD into brain tissue than generic industry-control formulations and 487% more than the original DehydraTECH technology, according to the company’s news release.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) 2.0 version of its patented DehydraTECH(TM) oral drug-delivery technology has demonstrated its power to deliver more cannabidiol (“CBD”) into the bloodstream than generic industry-control formulations (http://nnw.fm/SR9dw). An article discussing the company reads, “The company’s 2.0 technology is specifically being developed for effectiveness in helping to deliver its drug payload across the blood-brain barrier, a natural biological system of blood vessels and endothelial cells that bar most drugs from accessing the brain’s central-nervous-system hierarchy. The ability to effectively deliver drugs to the brain is of keen interest to developers of drugs designed to beneficially target the central nervous system. . . . Lexaria’s research and development showed that DehydraTECH version 2.0 was able to deliver 1,937% more CBD into brain tissue than generic industry-control formulations and 487% more than the original DehydraTECH technology, according to the company’s news release.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
1